دورية أكاديمية
أعرض في EDS

The TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation.

التفاصيل البيبلوغرافية
العنوان: The TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation.
المؤلفون: Reiser ML; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, USA., Mosaheb MM; Department of Microbiology, Boston University School of Medicine, Boston, USA.; Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, USA., Lisk C; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, USA., Platt A; Department of Microbiology, Boston University School of Medicine, Boston, USA., Wetzler LM; Department of Microbiology, Boston University School of Medicine, Boston, USA. lwetzler@bu.edu.; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, USA. lwetzler@bu.edu.
المصدر: Scientific reports [Sci Rep] 2017 Apr 07; Vol. 7 (1), pp. 736. Date of Electronic Publication: 2017 Apr 07.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Antigen Presentation/*immunology , Antigen-Presenting Cells/*immunology , Antigen-Presenting Cells/*metabolism , Cross-Priming/*immunology , Porins/*metabolism , Toll-Like Receptor 2/*metabolism, Animals ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Cell Movement/immunology ; Cell Proliferation ; Cytokines/metabolism ; Endosomes/metabolism ; Female ; Immunization ; Lymphoid Tissue/immunology ; Lymphoid Tissue/metabolism ; Lysosomes/metabolism ; Meningococcal Infections/immunology ; Meningococcal Infections/microbiology ; Mice ; Mice, Knockout ; Neisseria meningitidis/immunology ; Porins/immunology ; Protein Binding ; Toll-Like Receptor 2/genetics
مستخلص: TOLL-like receptor (TLR) ligands activate both innate and adaptive immune cells, while modulating the cellular immune response. The outer membrane protein (OMP) from Neisseria meninigitidis, PorB, is a naturally occurring TLR2 ligand and functions as an adjuvant. Here, we demonstrate that PorB increases the level of OVA in the endo-/lysosomal cellular compartment of BMDCs, increases antigen presenting cell (APC) trafficking to draining lymph nodes, and enhances antigen cross-presentation. PorB is capable of mounting an antigen specific T cell response by efficiently stimulating antigen cross-presentation in vivo and in vitro assessed by BMDC OT-I cocultivation assays. The enhanced antigen cross-presentation and the increased APC recruitment to secondary lymphoid tissues expand the scope of known adjuvant effects of PorB on the immune system. Our findings lead to a better understanding of how TLR-ligand based adjuvants can alter and modulate immune responses.
References: Immunol Rev. 2004 Jun;199:9-26. (PMID: 15233723)
Adv Drug Deliv Rev. 2011 Sep 10;63(10-11):909-22. (PMID: 21683103)
J Immunol. 2016 Mar 15;196(6):2439-43. (PMID: 26819202)
Cancer J. 2010 Jul-Aug;16(4):382-91. (PMID: 20693851)
J Exp Med. 2006 Feb 20;203(2):413-24. (PMID: 16461338)
J Immunol. 2014 Oct 15;193(8):4169-77. (PMID: 25225666)
Nat Commun. 2016 Jan 12;7:10332. (PMID: 26755131)
J Med Microbiol. 2012 Jul;61(Pt 7):889-894. (PMID: 22322337)
Curr Protoc Immunol. 2008 Nov;Chapter 14:14.1.1-14.1.14. (PMID: 19016445)
Vaccine. 1993 Sep;11(12):1199-204. (PMID: 8256501)
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10501-6. (PMID: 18650390)
J Immunol. 1990 Nov 1;145(9):3071-9. (PMID: 2120344)
Vaccine. 2008 Feb 6;26(6):786-96. (PMID: 18191311)
PLoS Pathog. 2008 Aug 29;4(8):e1000138. (PMID: 18769719)
J Immunol. 2011 Aug 15;187(4):1692-701. (PMID: 21742967)
Vaccine. 2008 Jan 24;26(4):552-61. (PMID: 18162266)
Vaccine. 2009 Jun 24;27(31):4219-24. (PMID: 19393709)
Oncoimmunology. 2013 Nov 1;2(11):e26403. (PMID: 24482744)
J Infect Dis. 1999 Sep;180(3):755-61. (PMID: 10438364)
Protein Expr Purif. 2005 Dec;44(2):136-46. (PMID: 16027004)
J Immunol. 2003 Jul 1;171(1):32-6. (PMID: 12816980)
J Infect Dis. 1992 Sep;166(3):551-5. (PMID: 1323620)
Adv Immunol. 2005;86:241-305. (PMID: 15705424)
J Immunol Methods. 1990 Dec 31;135(1-2):101-9. (PMID: 2125617)
Nat Rev Immunol. 2012 Jul 13;12(8):557-69. (PMID: 22790179)
J Immunol. 2003 Apr 15;170(8):4102-10. (PMID: 12682240)
J Exp Med. 2008 Apr 14;205(4):869-82. (PMID: 18362170)
Trends Immunol. 2006 Jan;27(1):49-55. (PMID: 16310411)
J Exp Med. 1988 Feb 1;167(2):658-63. (PMID: 3346624)
Front Immunol. 2012 Apr 18;3:79. (PMID: 22566960)
Immunity. 2014 Sep 18;41(3):478-492. (PMID: 25220212)
Vaccine. 2006 Apr 12;24 Suppl 2:S2-22-3. (PMID: 16823911)
Curr Opin Immunol. 2009 Feb;21(1):105-10. (PMID: 19342210)
J Exp Med. 2000 Dec 18;192(12):1685-96. (PMID: 11120766)
J Virol. 2011 Dec;85(24):13224-33. (PMID: 21957295)
Immunity. 2006 Oct;25(4):607-17. (PMID: 17027300)
Nature. 2006 Apr 6;440(7085):808-12. (PMID: 16489357)
J Immunol. 2003 Nov 15;171(10):5198-207. (PMID: 14607920)
J Exp Med. 1996 Mar 1;183(3):1151-9. (PMID: 8642257)
Eur J Immunol. 2015 Apr;45(4):1159-69. (PMID: 25529558)
PLoS One. 2013 Dec 11;8(12):e82171. (PMID: 24349212)
J Immunol. 2005 Mar 15;174(6):3545-50. (PMID: 15749891)
J Immunol Methods. 2007 Dec 1;328(1-2):204-14. (PMID: 17804011)
Clin Vaccine Immunol. 2008 Sep;15(9):1322-9. (PMID: 18614668)
Ann N Y Acad Sci. 1993 Aug 12;690:204-13. (PMID: 8368739)
Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15440-5. (PMID: 15489266)
Vaccine. 2005 Nov 16;23(46-47):5450-6. (PMID: 16006019)
Immunity. 2015 May 19;42(5):850-63. (PMID: 25979419)
J Biol Chem. 2007 Jul 20;282(29):21145-59. (PMID: 17462991)
Vaccine. 2012 Jun 13;30(28):4216-24. (PMID: 22542815)
Eur J Immunol. 2008 Aug;38(8):2068-71. (PMID: 18651701)
Immunity. 2010 Oct 29;33(4):492-503. (PMID: 21029960)
Int Immunol. 2005 Jan;17(1):1-14. (PMID: 15585605)
Nat Med. 2013 Dec;19(12):1597-608. (PMID: 24309663)
Blood. 2007 May 1;109(9):3890-4. (PMID: 17218388)
J Microsc. 2006 Dec;224(Pt 3):213-32. (PMID: 17210054)
Immunity. 1999 Oct;11(4):443-51. (PMID: 10549626)
Curr Opin Immunol. 2010 Jun;22(3):411-6. (PMID: 20466528)
J Clin Invest. 2015 Jun;125(6):2532-46. (PMID: 25938786)
Nat Med. 2014 Jan;20(1):47-53. (PMID: 24362933)
Eur J Immunol. 2008 May;38(5):1404-13. (PMID: 18389478)
Curr Top Med Chem. 2013;13(20):2597-608. (PMID: 24066890)
J Immunol. 2011 Sep 1;187(5):2172-80. (PMID: 21810614)
Cell. 2014 Jul 31;158(3):506-21. (PMID: 25083866)
معلومات مُعتمدة: R01 AI040944 United States AI NIAID NIH HHS; R56 AI040944 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (Cytokines)
0 (Porins)
0 (Toll-Like Receptor 2)
0 (porin protein, Neisseria)
تواريخ الأحداث: Date Created: 20170409 Date Completed: 20180830 Latest Revision: 20240326
رمز التحديث: 20240326
مُعرف محوري في PubMed: PMC5428659
DOI: 10.1038/s41598-017-00555-4
PMID: 28389664
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-017-00555-4